AstraZeneca is one of the world's leading pharmaceutical companies.
We provide innovative, effective medicines designed to fight disease in important areas of medical need: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory.
Our broad product portfolio includes many world leaders and a range of high potential therapies for treating cancer (Casodex, Arimidex and Faslodex), gastrointestinal disease ( Nexium), asthma ( Symbicort), hypertension ( Atacand), high cholesterol ( Crestor), migraine ( Zomig) and schizophrenia ( Seroquel).
Our products are available in over 100 countries.
Sales in 2006 totalled $26.5 billion with an operating profit of $8.2 billion.
We are committed to continued top tier financial performance alongside continued innovation.
We spend over $16 million every working day on the research and development of new medicines that meet patient needs. (Total R&D spend in 2006: $3.9 billion).
We employ 12,000 people in research and development at 12 R&D centres in 8 countries.
We have 27 manufacturing sites in 19 countries dedicated to ensuring we can deliver a secure, high quality, cost-effective supply of our product range around the world.
In total, we employ over 66,000 people worldwide: 58% in Europe, 27% in the Americas and 15% in the rest of the world.
Our corporate headquarters are in London, UK and our R&D headquarters are in Sodertalje, Sweden.
We combine our global capabilities with high quality relationships in local markets and focus on responding quickly and effectively to changing business needs.
With a global business comes a global responsibility and, along with our commitment to competitiveness and performance, we will continue to be led by our core values to achieve sustainable success.
